Cargando…
Novel p53 therapies for head and neck cancer
Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human pa...
Autores principales: | Castellanos, Mario R., Pan, Quintin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698513/ https://www.ncbi.nlm.nih.gov/pubmed/29204550 http://dx.doi.org/10.1016/j.wjorl.2016.05.005 |
Ejemplares similares
-
The current status of oncolytic viral therapy for head and neck cancer
por: Old, Matthew O., et al.
Publicado: (2016) -
Intra-tumor heterogeneity in head and neck cancer and its clinical implications
por: Mroz, Edmund A., et al.
Publicado: (2016) -
mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
por: Coppock, Joseph D., et al.
Publicado: (2016) -
Interleukin-6 role in head and neck squamous cell carcinoma progression
por: Choudhary, Moaz M., et al.
Publicado: (2016) -
The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer
por: Padariya, Monikaben, et al.
Publicado: (2022)